0270/2025 - Assistência Farmacêutica e a Incorporação de Psicotrópicos: Lacunas Terapêuticas e Oportunidades de Fortalecimento no SUS Pharmaceutical Assistance and the Incorporation of Psychotropics: Therapeutic Gaps and Opportunities for Strengthening the SUS
Analisar a evolução na incorporação de psicotrópicos à RENAME e se o atual elenco atende a carga dos transtornos mentais no Brasil. Foram levantadas as solicitações de psicotrópicos enviadas à CONITEC entre 2012 e dezembro de 2024 e foi analisado o número de psicotrópicos para transtornos mentais nas últimas oito versões da RENAME, comparando com a lista da OMS. Posteriormente, foi analisada a relação entre o número de psicotrópicos da RENAME 2024 e a carga de doença no Brasil segundo o indicador DALY. Foram enviadas 11 solicitações de psicotrópicos à CONITEC, equivalente a 1,0% do total. 90,9% das demandas referiam-se à incorporação e 9,1% à ampliação de uso. A maioria das demandas foi realizada pelo Ministério da Saúde, com taxa de aprovação de 70,0%. Entre 2010 e 2014, houve aumento na incorporação de psicotrópicos junto à RENAME; contudo, as RENAME seguintes não foram alteradas. A RENAME 2024 inclui 18 psicotrópicos e 66,7% são financiados pelo Componente Básico. Há relação desproporcional entre o número de medicamentos para ansiedade e depressão na RENAME frente à alta carga destas doenças no Brasil. Os achados apontam que a falta de revisão da RENAME pode estar impactando no atendimento das necessidades em saúde mental da população brasileira.
Palavras-chave:
Acesso a Medicamentos Essenciais e Tecnologias em Saúde; Carga Global da Doença; Transtornos Mentais; Sistema Único de Saúde.
Abstract:
To analyze the evolution in the incorporation of psychotropics into RENAME and whether the current list meets the burden of mental disorders in Brazil. Requests for psychotropics sent to CONITEC between 2012 and December 2024 were collected and the number of psychotropics for mental disorders in the last eight versions of RENAME was analyzed, comparing with the WHO list. Then, the relationship between the number of psychotropics in RENAME 2024 and the burden of disease in Brazil according to the DALY indicator was analyzed. 11 requests for psychotropics were sent to CONITEC, equivalent to 1.0% of the total. 90.9% of the demands referred to the incorporation and 9.1% to the expansion of use. Most demands were made by the Ministry of Health, with an approval rate of 70.0%. Between 2010 and 2014, there was an increase in the incorporation of psychotropics in RENAME, but the following RENAMEs were not changed. RENAME 2024 includes 18 psychotropics and 66.7% are funded by the Basic Component. There is a disproportionate relationship between the number of medications for anxiety and depression in RENAME and the high burden of these diseases in Brazil. The findings indicate that the lack of review of RENAME may be impacting on meeting the mental health needs of the Brazilian population.
Keywords:
Access to Essential Medicines and Health Technologies; Global Burden of Disease; Mental Disorders; Unified Health System.
Pharmaceutical Assistance and the Incorporation of Psychotropics: Therapeutic Gaps and Opportunities for Strengthening the SUS
Resumo (abstract):
To analyze the evolution in the incorporation of psychotropics into RENAME and whether the current list meets the burden of mental disorders in Brazil. Requests for psychotropics sent to CONITEC between 2012 and December 2024 were collected and the number of psychotropics for mental disorders in the last eight versions of RENAME was analyzed, comparing with the WHO list. Then, the relationship between the number of psychotropics in RENAME 2024 and the burden of disease in Brazil according to the DALY indicator was analyzed. 11 requests for psychotropics were sent to CONITEC, equivalent to 1.0% of the total. 90.9% of the demands referred to the incorporation and 9.1% to the expansion of use. Most demands were made by the Ministry of Health, with an approval rate of 70.0%. Between 2010 and 2014, there was an increase in the incorporation of psychotropics in RENAME, but the following RENAMEs were not changed. RENAME 2024 includes 18 psychotropics and 66.7% are funded by the Basic Component. There is a disproportionate relationship between the number of medications for anxiety and depression in RENAME and the high burden of these diseases in Brazil. The findings indicate that the lack of review of RENAME may be impacting on meeting the mental health needs of the Brazilian population.
Palavras-chave (keywords):
Access to Essential Medicines and Health Technologies; Global Burden of Disease; Mental Disorders; Unified Health System.
Valdivieso, D, Biglia, LV, Santana, RS, Mendes, SJ, Aguiar, PM. Assistência Farmacêutica e a Incorporação de Psicotrópicos: Lacunas Terapêuticas e Oportunidades de Fortalecimento no SUS. Cien Saude Colet [periódico na internet] (2025/ago). [Citado em 27/01/2026].
Está disponível em: http://cienciaesaudecoletiva.com.br/artigos/assistencia-farmaceutica-e-a-incorporacao-de-psicotropicos-lacunas-terapeuticas-e-oportunidades-de-fortalecimento-no-sus/19746?id=19746&id=19746
